Thrombosis and Haemostasis, Table of Contents Thromb Haemost 2023; 123(02): 133-134DOI: 10.1055/s-0042-1760129 Theme Issue Editorial Focus Continuous Improvement of Antiplatelet Therapy in Cardiovascular Disease Freek W.A. Verheugt 1 Department of Cardiology, Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, The Netherlands , Kurt Huber 2 3rd Department of Medicine, Cardiology and Intensive Care Medicine, Wilhelminen Hospital, Vienna, Austria › Author Affiliations Recommend Article Abstract Buy Article Full Text References References 1 Kim HK, Tantry US, Smith Jr SC. et al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost 2021; 121 (04) 422-432 2 Schrör K, Verheugt FWA, Trenk D. Drug-drug interaction between antiplatelet therapy and lipid lowering agents (statins and PCSK9 inhibitors). Thromb Haemost 2023; 123, In press 3 Sabatine MS, Giugliano RP, Keech AC. et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376 (18) 1713-1722 4 Schwartz GG, Steg PG, Szarek M. et al; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018; 379 (22) 2097-2107 5 Geisler T, Poli S, Huber K. et al. Resumption of antiplatelet therapy after major bleeding. Thromb Haemost 2022; 123, In press 6 Rikken SAOF, Storey RF, Andreotti F, Clemmensen P, Ten Berg JM. Parenteral antiplatelet drugs in ST-elevation myocardial infarction: current status and future directions. Thromb Haemost 2022; 123, In press 7 O'Donoghue ML, Murphy SA, Sabatine MS. The safety and efficacy of aspirin discontinuation on a background of a P2Y12 inhibitor in patients after percutaneous coronary intervention: a systematic review and meta-analysis. Circulation 2020; 142 (06) 538-545 8 Verheugt FWA, Huber K, Clemmensen P, Collet JP, Cuisset T, Andreotti F. Platelet P2Y12 inhibitor monotherapy after percutaneous coronary intervention: an emerging option of antiplatelet therapy de-escalation. Thromb Haemost 2023; 123, In press
